NCT00402233 - A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

September 30, 2008

Conditions

Parkinson Disease

Interventions

DRUG

Pramipexole

DRUG

Placebo

Trial Locations (39)

Unknown

248.622.170 Boehringer Ingelheim Investigational Site, Phoenix

248.622.112 Boehringer Ingelheim Investigational Site, Little Rock

248.622.69 Boehringer Ingelheim Investigational Site, Fountain Valley

248.622.198 Boehringer Ingelheim Investigational Site, La Jolla

248.622.111 Boehringer Ingelheim Investigational Site, Oxnard

248.622.61 Boehringer Ingelheim Investigational Site, Sacramento

248.622.23 Boehringer Ingelheim Investigational Site, San Diego

248.622.73 Boehringer Ingelheim Investigational Site, San Francisco

248.622.108 Boehringer Ingelheim Investigational Site, Denver

248.622.190 Boehringer Ingelheim Investigational Site, Danbury

248.622.215 Boehringer Ingelheim Investigational Site, Manchester

248.622.196 Boehringer Ingelheim Investigational Site, Boca Raton

248.622.14 Boehringer Ingelheim Investigational Site, Miami

248.622.149 Boehringer Ingelheim Investigational Site, Weston

248.622.139 Boehringer Ingelheim Investigational Site, Honolulu

248.622.5 Boehringer Ingelheim Investigational Site, Chicago

248.622.138 Boehringer Ingelheim Investigational Site, Springfield

248.622.87 Boehringer Ingelheim Investigational Site, Louisville

248.622.207 Boehringer Ingelheim Investigational Site, New Orleans

248.622.132 Boehringer Ingelheim Investigational Site, Shreveport

248.622.17 Boehringer Ingelheim Investigational Site, Boston

248.622.40 Boehringer Ingelheim Investigational Site, Boston

248.622.76 Boehringer Ingelheim Investigational Site, Boston

248.622.186 Boehringer Ingelheim Investigational Site, East Lansing

248.622.77 Boehringer Ingelheim Investigational Site, Omaha

248.622.155 Boehringer Ingelheim Investigational Site, Lebanon

248.622.135 Boehringer Ingelheim Investigational Site, Brooklyn

248.622.216 Boehringer Ingelheim Investigational Site, Kingston

248.622.202 Boehringer Ingelheim Investigational Site, New York

248.622.86 Boehringer Ingelheim Investigational Site, New York

248.622.1 Boehringer Ingelheim Investigational Site, Rochester

248.622.89 Boehringer Ingelheim Investigational Site, Cincinnati

248.622.20 Boehringer Ingelheim Investigational Site, Columbus

248.622.169 Boehringer Ingelheim Investigational Site, Hershey

248.622.18 Boehringer Ingelheim Investigational Site, Philadelphia

248.622.199 Boehringer Ingelheim Investigational Site, Houston

248.622.7 Boehringer Ingelheim Investigational Site, Houston

248.622.213 Boehringer Ingelheim Investigational Site, Spokane

248.622.104 Boehringer Ingelheim Investigational Site, Milwaukee